Immunotherapy prostate cancer drug gives 'amazing results'
Researchers say it helped extended the lives of men who were "basically dying" and had tried every other treatment.  
Men given just months or weeks to live after being diagnosed with prostate cancer are surviving for more than a year thanks to a breakthrough in immunotherapy treatment, a trial has shown.
Almost 40% of patients who spent 12 months on the drug pembrolizumab - known as a "checkpoint inhibitor" - as part of a new study were still alive and one in 10 had not seen the cancer grow.
The 258 men with advanced prostate cancer were treated with the drug as part of a trial led by a team at the Institute of Cancer Research (ICR) in London and the Royal Marsden NHS Foundation Trust.
The results - which are to be presented at the American Society of Clinical Oncology annual meeting in Chicago - have been lauded as "amazing".

Share To:

captain dozy

Post A Comment:

0 comments so far,add yours